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Abstract
Resistance rates are increasing among several problematic Gram-
negative pathogens that are often responsible for serious
nosocomial infections, including Acinetobacter spp.,  Pseudo-
monas aeruginosa, and (because of their production of extended-
spectrum  β-lactamase) Enterobacteriaceae. The presence of
multiresistant strains of these organisms has been associated with
prolonged hospital stays, higher health care costs, and increased
mortality, particularly when initial antibiotic therapy does not
provide coverage of the causative pathogen. Conversely, with high
rates of appropriate initial antibiotic therapy, infections caused by
multiresistant Gram-negative pathogens do not negatively
influence patient outcomes or costs. Taken together, these
observations underscore the importance of a ‘hit hard and hit fast’
approach to treating serious nosocomial infections, particularly
when it is suspected that multiresistant pathogens are responsible.
They also point to the need for a multidisciplinary effort to combat
resistance, which should include improved antimicrobial steward-
ship, increased resources for infection control, and development of
new antimicrobial agents with activity against multiresistant Gram-
negative pathogens.
Introduction
The treatment of serious bacterial infections in clinical
practice is often complicated by antibiotic resistance. Based
on their clinical experience, most clinicians - but not all [1,2] -
believe that antibiotic resistance is increasing, is associated
with increased morbidity and mortality, and is expensive. The
importance of each of these points depends on the person’s
perspective: the first is most important to clinicians, the
subsequent two to patients, and finally the last point to
hospital administrators and health care payors. Recognizing
the growing problem of antibiotic resistance, as well as the
decreasing investment being made in antimicrobial research
and development, the Infectious Diseases Society of America
created the Antimicrobial Availability Task Force in March
2003 [3]. This group of national experts was charged with
reviewing trends in antibiotic research and development in
concert with the rise in antibiotic resistance and then
proposing various solutions to ensure the availability of
effective antibiotics in the future. Their policy report, issued in
July 2004, was entitled ‘Bad bugs, no drugs: as antibiotic
R&D stagnates, a public health crisis brews’. Although the
report has had a favorable impact on government legislation,
much more remains to be done.
The Antimicrobial Availability Task Force identified six
particularly problematic pathogens, including three Gram-
negative organisms: Acinetobacter baumannii, extended-
spectrum β-lactamase (ESBL)-producing Enterobacteriaceae,
and  Pseudomonas aeruginosa. The other problematic
organisms were the Gram-positive pathogens methicillin-
resistant  Staphylococcus aureus (MRSA) and vancomycin-
resistant Enterococcus faecium, and the filamentuous fungi
Aspergillus spp. [3]. Without a doubt, MRSA is the organism
that has received the most attention, largely driven by clinical
need rather than by large sums of money. It is likely that
interest in the other problematic pathogens will also be driven
by clinical need and not by investment to increase awareness.
Some experts consider two additional water-borne, non-
fermenting Gram-negative pathogens, namely Stenotropho-
monas maltophilia and Burkholderia cepacia, both of which
are related to P. aeruginosa, to be problematic organisms [4].
Gram-negative pathogens of concern in
nosocomial infections
Acinetobacter spp.
Although long thought to be relatively avirulent, the Acineto-
bacter calcoaceticus-baumannii complex is emerging as a
multiresistant nosocomial and community-acquired pathogen
[3]. It was the most common wound isolate in Vietnam,
Desert Storm, and Middle East war injuries, as well as in
wounds associated with the 2004 Asian tsunami [5,6]. It is
unclear whether the source of A. baumannii is associated
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with field hospitals or larger medical centers after the soldiers
were evacuated from the war zone. Nevertheless, treatment
of soldiers with infected wounds is now directed to ensure
coverage of this pathogen.
A. baumannii is an increasingly common cause of ventilator-
associated pneumonia (VAP). In recent years, many things
have changed in how VAP is treated. VAP patients are now
routinely given shorter courses of antibiotic therapy (7 to
10 days), except in cases caused by P. aeruginosa. However,
despite efforts to use Acute Physiology and Chronic Health
Evaluation (APACHE) II or other scores, there remains a need
to improve patient evaluation during antibiotic therapy. Does
the patient still have adult respiratory distress syndrome? Is
the patient still acidotic? How bad is the multiple organ
system failure? In an increasing number of cases, at least in
Germany and at the Walter Reed Army Medical Center
(Washington, DC), VAP caused by A. baumannii presents as
a multilobar infiltrate that often cavitates and develops pleural
effusions and fistula formation. It is not uncommon in such
cases to find persistently positive endotracheal specimens or
open-lung biopsies with multiresistant strains of A. baumannii
(resistant to three or more representatives of the major
antibiotic categories) [7]. Data from the National Nosocomial
Infections Surveillance (NNIS) system indicate that the
incidence of nosocomial infections caused by Acinetobacter
spp. increased between 1975 and 2003 (Figure 1) [8].
The incidence of Acinetobacter spp. in nosocomial pneumonia
increased from 1.5% to 6.9% during this period, and similarly
the incidence in bloodstream infections increased from 1.8%
to 2.4%, in surgical site infections from 0.5% to 2.1%, and in
urinary tract infections from 0.6% to 1.6%. Importantly,
multiresistant strains of Acinetobacter spp. are being isolated
with increasing frequency in many of these nosocomial
infections. These pathogens have rapidly developed resis-
tance to currently available antimicrobials via a wide range of
mechanisms, including production of aminoglycoside-modify-
ing enzymes, ESBLs, and carbapenemases, as well as
through changes in outer membrane proteins, penicillin-
binding proteins, and topoisomerases [9,10]. It is therefore
not surprising that Acinetobacter  spp. have emerged as
‘selected’ pathogens. In many areas it is common to find
strains of Acinetobacter spp. that are resistant to all amino-
glycosides, cephalosporins, and fluoroquinolones [11]. As a
result, empiric therapy has become problematic and relapses
more common. It is important to remember that Acinetobacter
infections occur in intensive care units (ICUs), postoperative
suites, and other hospital settings where antibiotic treatment
is initially overseen by intensivists and hospitalists and not by
infectious disease specialists. The importance of early
aggressive treatment of Acinetobacter cannot be stressed
enough.
The impact that multiresistant Acinetobacter  spp. have on
patient outcome is illustrated by a recent retrospective, risk-
adjusted, cohort study conducted in patients with
Acinetobacter  bacteremia [12]. Patients infected with
imipenem-resistant strains had a significantly higher 30-day
mortality rate than did those infected with imipenem-suscep-
tible strains (57.5% versus 27.5%; P = 0.007; Figure 2). In
the vast majority of cases the imipenem-resistant stains had a
multidrug resistance phenotype, characterized by resistance
to three or more other antibiotic classes. Notably, patients
with imipenem-resistant strains were significantly more likely
to receive inappropriate antibiotic therapy initially that did not
provide coverage against the isolated Acinetobacter strain
(65.0% versus 20.0%; P < 0.001). Moreover, patients who
were treated inappropriately at the start had a higher 30-day
mortality rate than did those given appropriate initial antibiotic
therapy (67.6% versus 23.9%; P < 0.001). The difference
between groups in mortality was particularly evident over the
first 5 days, indicating that initial treatment is of paramount
importance.
Figure 1
Acinetobacter spp. and Pseudomonas aeruginosa isolates: 1975 and 2003. Shown are the percentages of bacterial isolates associated with (a)
Acinetobacter spp. and (b) P. aeruginosa by infection type in the National Nosocomial Infections Surveillance System for 1975 and 2003. Data
from 1975 are from hospital-wide surveillance whereas those from 2003 are from intensive care unit surveillance [8].Page 3 of 7
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ESBL-producing Enterobacteriaceae
The most common mechanism of resistance among Escheri-
chia coli, Klebsiella pneumoniae, and other Enterobacteria-
ceae is through the production of β-lactamases, which -
depending on the enzyme - inactivate certain β-lactam anti-
biotics [13]. The ESBLs are a heterogeneous group of
enzymes that are encoded by plasmid-borne genes. ESBLs
now number 532 distinct enzymes and convey varying
degrees of resistance to cephalosporins, penicillins, β-lacta-
mase inhibitors, and monobactams [1,13]. The prevalence of
ESBL-producing strains varies by geography (particularly in
urban areas), type of hospital, and patient age. For example,
in the SENTRY Antimicrobial Surveillance Program, the rate
of ESBL-producing strains of Klebsiella spp. in bloodstream
infections between 1997 and 2002 was 43.7% in Latin
America but 21.7% in Europe and 5.8% in North America
(P < 0.001) [14]. Among North American strains recovered in
2001 from patients in ICUs, the ESBL-producing phenotype
was found in 11.2% of E. coli isolates and 16.2% of Kleb-
siella spp. [15]. Importantly, during the past 2 to 3 years there
have been reports of ESBL-producing strains that also
produce carbapenemases [16].
The impact that ESBL production has on patient outcome
and hospital costs was evaluated in a recent matched-cohort
study [17]. Twenty-one patients infected with ESBL-produ-
cing E. coli or Klebsiella spp. at sites other than the urinary
tract were compared with 21 patients with non-ESBL
infections matched for pathogen, patient age, co-morbid
conditions, anatomic site of infection, hospital location, date
of hospitalization, and initial antibiotics received. The two
groups were well matched with respect to demographic and
clinical characteristics, except that patients with ESBL-
positive strains had been hospitalized for a longer period
before onset of the infection (24 days versus 11 days;
P = 0.035) and were more likely to have recently received
antibiotics (42.9% versus 4.8%; P = 0.027). Patients infected
with ESBL-producing strains had significantly higher
infection-related hospital costs than did those with non-
ESBL-producing strains ($41,353 versus $24,902 per
patient; P = 0.034), which was largely driven by a prolonged
length of stay in the hospital. Patients with ESBL-producing
strains required an additional length of stay of 9.7 days (95%
confidence interval 3.2 days to 14.6 days; P = 0.006). In both
groups, hospital bed costs accounted for approximately 55%
of total costs, whereas antibiotic costs represented only 2%
to 3% of the total. Initial antibiotic therapy was less likely to
be successful in patients infected with the ESBL-positive
strains (47.6% versus 85.7%; P = 0.027), reflecting a differ-
ence in success rates for noncarbapenem β-lactam anti-
biotics and fluoroquinolones. In contrast, treatment was
successful in all patients who received a carbapenem,
regardless of ESBL phenotype. Patients who failed initial
antibiotic therapy were significantly more likely to receive
sequential antibiotic therapy, thus increasing their length of
stay and hospital costs.
Similar results were obtained in an earlier case-control study
involving 33 patients infected with ESBL-producing E. coli or
K. pneumoniae and 66 matched control individuals [18].
Patients with ESBL-producing strains had significantly
greater median hospital charges than did those with non-
ESBL-producing strains ($66,590 versus $22,231 per
patient; P < 0.001). On multivariate analysis, which controlled
for APACHE II score and hospitalization duration before
infection, ESBL-producing strains increased costs by an
average of 1.71-fold (95% confidence interval 1.01-fold to
2.88-fold; P = 0.04) relative to controls. Hospital stays were
also 1.7 times longer after correction for APACHE II scores
(P = 0.01), although this difference largely disappeared when
correction was also made for the duration of hospitalization
before infection.
A larger case-control study compared 99 bacteremic patients
with ESBL-producing strains of E. coli, Klebsiellia  spp., or
Proteus spp. with 99 control patients with bacteremia caused
by non-ESBL strains [19]. Patients with ESBL-positive strains
had significantly higher average hospital costs ($46,970
versus $16,877 per patient; P < 0.001), longer median
hospital stays after the onset of bacteremia (11 days versus
5 days;  P < 0.001), and higher in-hospital mortality (35%
versus 18%; P = 0.01) compared with control individuals.
After adjusting for potential confounding variables in
multivariate analyses, ESBL production remained indepen-
dently associated with increased hospital costs (P = 0.003),
longer hospital stays (P = 0.001), and higher in-hospital
mortality (P = 0.008). Moreover, patients with ESBL-positive
strains were much more likely than control individuals to have
a delay of at least 48 hours until initiation of appropriate
antibiotic therapy (66% versus 7%; P < 0.001).
The importance of selecting appropriate initial antibiotic
therapy to patient outcome is illustrated by a prospective
Available online http://ccforum.com/content/12/S4/S4
Figure 2
Impact of imipenem resistance on mortality of patients with
Acinetobacter bacteremia. Reprinted with permission from Kwon and
coworkers [12]. Copyright © 2007 Oxford University Press.study of 455 consecutive cases of K. pneumoniae at 12
hospitals in seven countries [20]. Eighty-five cases were
caused by an ESBL-producing strain, and of these 20
patients (23.5%) died within 14 days of the first positive
blood culture. Failure to administer an appropriate antibiotic
with in vitro activity against the isolate within the first 5 days
resulted in significantly higher mortality than treatment with an
appropriate antibiotic (63.6% versus 14.1%; P = 0.001).
Patients who received a carbapenem - either alone or in
combination with another antibiotic - during that 5-day period
had 83% lower risk for 14-day mortality than did those who
received noncarbapenem antibiotics (P = 0.012). Moreover,
on multivariate analysis carbapenem use was found to be
independently associated with decreased mortality.
Taken together, these studies consistently show that ESBL-
producing Enterobacteriaceae are associated with a delay in
initiation of appropriate antibiotic therapy, which conse-
quently prolongs hospital stays and increases hospital costs.
More importantly, failure to initiate appropriate antibiotic
therapy from the start appears to be responsible for higher
patient mortality.
P. aeruginosa
P. aeruginosa is an invasive Gram-negative bacterial
pathogen that is responsible for a wide range of severe
nosocomial infections, including pneumonia, urinary tract
infections, and bacteremia [3]. Importantly, this pathogen is
intrinsically susceptible to only a limited number of
antibacterial agents because of the low permeability of its cell
wall [21]. Consequently, infections are often difficult to treat
and may be life-threatening, particularly if the causative strain
is multiresistant. As a result, considerable attention has been
focused on P. aeruginosa in the hospital setting. As for A.
baumannii, the incidence of P. aeruginosa in most noso-
comial infections increased between 1975 and 2003
according to the NNIS System (Figure 1) [8]. During this
period, the incidence of P. aeruginosa increased from 9.6%
to 18.1% in nosocomial pneumonia, from 9.3% to 16.3% in
urinary tract infection, and from 4.7% to 9.5% in surgical site
infection. However, it declined slightly from 4.8% to 3.4% in
bloodstream infections, largely reflecting the increasing
frequency of certain Gram-positive pathogens, particularly
coagulase-negative staphylococci and enterococci. In the
2001 SENTRY Surveillance Program report [15], P. aeru-
ginosa was the second most common pathogen isolated
from ICU patients, trailing only S. aureus [15].
In addition to its intrinsic resistance, P. aeruginosa has also
acquired resistance via multiple mechanisms, including
production of β-lactamases and carbapenemases, upregula-
tion of multidrug efflux pumps, and finally cell wall mutations
leading to a reduction in porin channels [21]. Many small
antibiotics, including β-lactams and quinolones, require these
aqueous porin channels in order to enter P. aeruginosa. In
addition, mutation of genes encoding antibacterial targets
such as DNA gyrase for fluoroquinolones contributes to
resistance in P. aeruginosa. According to the NNIS System,
resistance in P. aeruginosa is increasing. For nosocomial
infections in ICU patients, 32% of strains were resistant to
third-generation cephalosporins (cefepine or ceftazidine) in
2003, representing a 9% increase over the preceding 5-year
period [22]. Similarly, 30% of strains were resistant to
fluoroquinolones, representing a 15% increase. Perhaps
most alarming was the observation that 21% of strains were
resistant to imipenem in 2003, which represented a 47%
increase over the previous 5-year period. These findings
indicate that using these antibiotics to treat nosocomial
infections caused by P. aeruginosa will result in a significant
number of clinical failures.
The impact that multidrug resistance in P. aeruginosa has on
mortality and cost is illustrated by several studies. In a retro-
spective analysis of patients with P. aeruginosa bacteremia at
a large university hospital over a 10-year period, 51 out of
358 cases (14.2%) were multiresistant to ciprofloxacin,
ceftazidime, imipenem, gentamicin, and piperacillin [23].
Patients with multiresistant P. aeruginosa had significantly
higher in-hospital mortality than did those with more
susceptible strains (67% versus 23%; P = 0.001). In another
study, multiresistant P. aeruginosa was isolated from 22
hospitalized patients [24]. The mean cost of admission in this
cohort was $54,081 per patient, which was substantially
higher than the $22,116 cost per patient for those infected
with susceptible strains of P. aeruginosa.
The emergence of resistance during treatment of P.
aeruginosa infections has a dramatic effect on outcome and
cost. In a cohort of 468 patients with P. aeruginosa
infections, 30 patients developed resistance during treat-
ment, defined by a fourfold increase in minimum inhibitory
concentration (MIC) relative to the baseline isolate, which
resulted in a change in interpretive class [25]. In the
multivariate analysis, patients in whom resistance emerged
had significantly longer median hospital stays (24 days versus
7 days;  P < 0.001) and higher in-hospital mortality rates
(27% versus 8%; P = 0.02) than did those who did not have
treatment-emergent resistance. Comparable results have
been reported for treatment-emergent resistance in other
Gram-negative pathogens, such as Enterobacter spp. [26].
Clinical challenges in treating patients with
resistant organisms
The clinical studies highlighted in the preceding sections
illustrate that patients infected with resistant strains of key
Gram-negative pathogens have increased mortality, longer
hospital stays, and higher hospital costs than those infected
by susceptible strains. This evidence underscores the need
for hospitals to start reacting in a proactive manner rather
than in a reactive one to combat the rising resistance rates.
Although resistance is an important factor, it is important to
recognize that several other problems also contribute to poor
Critical Care    Vol 12 Suppl 4 Slama
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of initial antibiotic therapy before susceptibility test results
become available. Patients who receive inadequate initial
antibiotic therapy that does not provide coverage of the
causative pathogen have poorer clinical outcomes, longer
lengths of stay, and higher costs than those who received an
appropriate antibiotic from the start [4]. Second, clinical
laboratories are struggling to provide optimal and rapid
susceptibility testing. However, hospitalists and intensivists
often may not recognize subtle differences in susceptibility
results. An MIC of 4 μg/ml for one drug does not mean that
the pathogen has an MIC of 4 μg/ml for all members of that
drug class. In turn, this may lead to slower identification of
resistant pathogens and, ultimately, poorer clinical outcomes.
Finally, efforts by hospital administrators to continually cut
costs may lead to elimination of key personnel involved in
overseeing infection control on a daily basis.
If resistant pathogens and inappropriate initial antibiotic
therapy are associated with poor outcomes and high costs,
then, conversely, high rates of appropriate initial antibiotic
therapy should overcome any difference in outcomes and
costs between resistant and susceptible strains. In a
retrospective, observational cohort study, 328 patients
admitted to the ICU were identified with nosocomial, micro-
biologically documented Gram-negative bacteremia [27]. Of
these, 120 cases (36.6%) were caused by ceftazidime-resis-
tant pathogens, which in the study hospital was considered
to indicate an ESBL-producing strain or a hyperproducer of
Amp C β-lactamases. Patients with susceptible and resistant
strains had similar demographic and clinical characteristics at
the onset of Gram-negative bacteremia, except that patients
with resistant strains had been hospitalized longer before
bacteremia onset than those with susceptible strains (18
versus 8 days; P < 0.001). In general, patients with resistant
strains were more likely to be infected with Acinetobacter
spp. and Enterobacter spp., whereas those with susceptible
strains were more likely to be infected with E. coli. The
frequencies of infection with other Enterobacteriaceae and P.
aeruginosa were similar in the two groups. Overall, appro-
priate initial antibiotic therapy was administered to 93.1% of
patients with susceptible stains and 91.1% of those with
resistant strains. Notably, mortality rates - whether measured
in the hospital or at 14 or 28 days - did not differ between
bacteremic patients with susceptible or resistant strains
(Figure 3). Although patients with resistant strains required,
on average, at least 1 additional week in the hospital, the
length of hospital stay after bacteremia onset did not differ.
The cost of Gram-negative resistance is further illustrated by
a recent study of 617 surgical patients with Gram-negative
rod infections [28]. In this analysis, antibiotic resistance was
defined by resistance to all drugs in one or more of the major
antibiotic classes. Patients with infection caused by resistant
bacteria had greater severity of illness at admission than did
those with susceptible strains; there was a higher rate of use
of invasive support measures at the time infection was
diagnosed among these patients. The most common
pathogens responsible for resistant infections were Pseudo-
monas  and  Acinetobacter  spp. After taking differences in
baseline parameters into account in the regression analysis,
antibiotic resistance independently predicted higher hospital
costs, with an attributable cost increase of $10,255 per
patient (P = 0.0001).
Real costs of controlling infection
Several factors contribute to the real costs associated with
controlling infection. These include the cost of new
antimicrobial development - now estimated at $1 billion per
drug - as well as the need for increased surveillance within
each hospital to determine which pathogens are problematic
by patient type and by hospital ward. The costs associated with
enforced isolation procedures to control spread of resistant
pathogens, as well as those for implementing improved
antibiotic usage policies to limit emergence of resistant strains,
must also be considered, but these will only be successful if
they are supported by the hospital administration. Finally,
education remains a critical component of any effort to control
infection, but it will most likely be successful when targeted to
interns, residents, and medical students who have not yet
developed specific treatment habits.
As the general population ages and people live longer,
additional strain will be placed on the delivery of quality health
care at reasonable prices. Whether the focus is on infection
control or another health care issue, who is going to help?
Large pharmaceutical companies will only develop new
antimicrobial agents if the federal government provides
financial incentives through better patent protection or
acceptable reimbursement rates. If it does not, then antibiotic
development will become the purview of small companies,
Available online http://ccforum.com/content/12/S4/S4
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Figure 3
Impact of high rates of appropriate antibiotic therapy on mortality in
patients with Gram-negative bacteremia. Antibiotic resistance was
defined as in vitro resistance to ceftazidime [27]. Reprinted with
permission. Copyright © 2002 Infectious Diseases Society of America.which will be bought and sold as they move agents through
the clinical development process. Hospitals will initiate
surveillance programs or policy changes in order to improve
infection control but only if they prove to save money.
Similarly, third-party payors will support use of new antibiotics
or procedures provided that they can maintain profit margins.
Legislators may help depending on where and how much
national pressure is delivered by various organizations and
lobbyists. Finally, physicians will take steps to improve
infection control, but they will require evidence, and then they
still will often make individual decisions rather than following a
recommended algorithm for patient management.
The list of new antimicrobials in clinical development for
treatment of Gram-negative infections unfortunately remains
small. Some of these agents are promising, especially the
carbapenems and cephalosporins currently in development,
because they have greater activity than other members of
their respective antibiotic class against key pathogens such
as P. aeruginosa and MRSA.
Conclusion
In summary, A. baumannii, ESBL-producing Enterobacteria-
ceae, and P. aeruginosa are key Gram-negative pathogens
that are involved in serious nosocomial infections.
Multiresistant strains are particularly problematic, conveying
increased mortality, longer hospital stays, and higher hospital
costs over and above the values associated with susceptible
strains of these pathogens. Moreover, the consistency of
these findings across studies, as well as across these key
pathogens, underscores the clinical and economic
significance of antibiotic resistance. Successful treatment
requires a ‘hit hard and hit fast’ approach with an antibiotic
that provides coverage of these important Gram-negative
organisms, including multiresistant strains. Finally, co-
operation between doctors, hospital administrators, third-
party payors, legislators, and pharmaceutical companies is
needed in order to find ways to prevent further increases in
antibiotic resistance and limit the costs associated with it.
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